当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?

Hematopoietic progenitor cell mobilization and harvesting in children with malignancies: do the advantages of pegfilgrastim really translate into clinical benefit?

Abstract：

:Our purpose was to assess success rates in children of achieving optimal hematopoietic progenitor cells (HPCs) harvest after mobilization with 300 microg/kg pegfilgrastim. Between January 2005 and January 2007, 26 children with solid malignancies who were referred for HPC collection were consecutively included. Hematopoietic progenitor cell mobilization consisted of one s.c. injection of 300 microg/kg body weight (BW) of pegfilgrastim. The success criterion was defined as at least 5 x 10(6) CD34+ cells/kg during the first standard apheresis (less than 3 blood volumes processed (BVP)). After 26 inclusions, the Bayesian analysis gave a mean estimated success rate of 60.7% (95% credibility interval: 42.0-78.0%). The first apheresis allowed the collection of 8.3 x 10(6) CD34+ cells/kg BW (range 0.6-37.8), with a median of 2.8 BVP (range 1.4-3.0). Overall, the median of CD34+ cells collected was 12.4 x 10(6)/kg (range 2.7-37.8). The cumulative dose of anthracyclin was the only variable associated with the total number of CD34+ collected cells (P<0.05). Mobilization was clinically well tolerated in 20 patients. No drug-related adverse events of grade > or =3 occurred. We conclude that a single injection of 300 microg/kg pegfilgrastim in the hematological steady state is an efficient and well-tolerated method of HPC mobilization in children with solid malignancies.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Merlin E,Zohar S,Jérôme C,Veyrat-Masson R,Marceau G,Paillard C,Auvrignon A,Le Moine P,Gandemer V,Sapin V,Halle P,Boiret-Dupré N,Chevret S,Deméocq F,Dubray C,Kanold J

doi

10.1038/bmt.2008.412

subject

Has Abstract

pub_date

2009-06-01 00:00:00

pages

919-25

issue

12

eissn

0268-3369

issn

1476-5365

pii

bmt2008412

journal_volume

43

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.

    abstract：:The clinical outcome of advanced-stage Extranodal NK/T cell lymphoma (ENKTL) patients using conventional chemotherapy is extremely poor. The aim of this study was to investigate the outcomes of advanced-stage ENKTL patients treated with non-anthracycline-based chemotherapy followed by upfront autologous stem cell tran...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01160-2

    authors： Song GY,Yoon DH,Suh C,Moon JH,Baek DW,Kim JS,Lee GW,Yi JH,Park Y,Jung KS,Kim SJ,Yang DH,Kim WS

    更新日期：2020-12-04 00:00:00

  • SCT in Jehovah's Witnesses: the bloodless transplant.

    abstract：:Auto-SCT and Allo-SCT are procedures conventionally associated with intensive transfusion support. This dependence has historically prevented SCT in individuals with religious or personal objections to transfusion. More recently, a growing body of literature supports the feasibility of 'bloodless transplants': SCT wit...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2008.5

    authors： Sloan JM,Ballen K

    更新日期：2008-05-01 00:00:00

  • Herpes simplex infection of the jejunum occurring in the early post-transplantation period.

    abstract：:Reactivation of infections with herpes viruses is a frequent and major cause of morbidity after bone marrow transplantation. In this case report we stress that HSV infections of the colon and small intestine should be considered in the differential diagnosis of diarrhea and intestinal bleeding in the early post-transp...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700995

    authors： Kingreen D,Nitsche A,Beyer J,Siegert W

    更新日期：1997-12-01 00:00:00

  • Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation.

    abstract：:Donor lymphocyte infusions (DLI) are used to treat relapsed haematological diseases after allogeneic stem cell transplantation (SCT). We treated seven patients with DLI for indolent non-Hodgkin's lymphoma relapsed after SCT. In available blood and bone marrow samples, lymphoma cells were analysed by real-time quantita...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704290

    authors： Mandigers CM,Verdonck LF,Meijerink JP,Dekker AW,Schattenberg AV,Raemaekers JM

    更新日期：2003-12-01 00:00:00

  • Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT.

    abstract：:Autologous stem cell transplantation (ASCT) was performed in 95 patients with chronic myelogenous leukemia (CML) in chronic phase and their data were reported to the European Bone Marrow Transplant Registry. Most patients presented bad prognostic factors. The results were analysed by September 1, 1993. The actuarial p...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Reiffers J,Goldman J,Meloni G,Cahn JY,Faberes C,Apperley J

    更新日期：1994-01-01 00:00:00

  • Evaluation of optimal survival of primitive progenitor cells (LTC-IC) from PBPC apheresis products after overnight storage.

    abstract：:Optimal overnight (ON) storage of PBPC aphereses is becoming an increasingly important issue and different options for storing PBPC products exist. The survival of primitive progenitor cells is of major interest, as recent data suggest that these progenitors are not only important for long-term engraftment but also co...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702104

    authors： Petzer AL,Gunsilius E,Zech N,Clausen J,Hoflehner E,Nussbaumer W,Gastl G

    更新日期：2000-01-01 00:00:00

  • Granisetron in the prevention of irradiation-induced emesis.

    abstract：:A double-blind double-dummy, comparative study was carried out in 30 patients receiving highly emetogenic fast dose rate, single fraction total body irradiation prior to bone marrow transplantation. Patients were randomised into one of two groups, receiving either granisetron, a specific 5-HT3 antagonist or a combinat...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：

    authors： Prentice HG,Cunningham S,Gandhi L,Cunningham J,Collis C,Hamon MD

    更新日期：1995-03-01 00:00:00

  • Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients.

    abstract：:Reconstitution of the adaptive immune system following allogeneic hematopoietic stem cell transplantation is crucial for beneficial outcome and is affected by several factors, such as GvHD and graft source. The impact of these factors on immune reconstitution has been thoroughly investigated during the early phase aft...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2017.216

    authors： Gaballa A,Norberg A,Stikvoort A,Mattsson J,Sundberg B,Uzunel M,Remberger M,Uhlin M

    更新日期：2018-01-01 00:00:00

  • Utilization of stored autologous PBSCs to support second autologous transplantation in multiple myeloma patients in the era of novel agent therapy.

    abstract：:Outcomes in multiple myeloma (MM) have improved significantly with novel agent therapy and autologous stem cell transplantation (ASCT). ASCTs are typically planned as either tandem or a single transplant with additional stored PBSCs available for a second salvage transplant. To accommodate these strategies, many cente...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2015.13

    authors： Phipps C,Linenberger M,Holmberg LA,Green D,Becker P,Connelly-Smith L,Klippel Z,Burwick N,Gopal A,Bensinger WI,Libby E

    更新日期：2015-05-01 00:00:00

  • T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.

    abstract：:Availability of an HLA-identical sibling (MRD) or suitably matched unrelated donor (MUD) has historically been a limiting factor in the application of allogeneic hematopoietic transplantation. Although almost all patients have an HLA-haploidentical family donor, prior attempts at transplantation from such donors using...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2014.62

    authors： Bashey A,Solomon SR

    更新日期：2014-08-01 00:00:00

  • Scoring system for clinically significant CMV infection in seropositive recipients following allogenic hematopoietic cell transplant: an SFGM-TC study.

    abstract：:In order to identify cytomegalovirus (CMV)-seropositive patients who are at risk of developing CMV infection following first allogeneic hematopoietic cell transplantation (allo-HCT), we built up a scoring system based on patient/donor characteristics and transplantation modalities. To this end, 3690 consecutive patien...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01178-6

    authors： Beauvais D,Drumez E,Blaise D,Peffault de Latour R,Forcade E,Ceballos P,Uyttebroeck A,Labussière H,Nguyen S,Bourhis JH,Chevallier P,Thiebaut A,Poiré X,Maury S,Deconinck E,Cluzeau T,Brissot E,Huynh A,Rubio MT,Duhamel

    更新日期：2020-12-18 00:00:00

  • Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS.

    abstract：:The COVID-19 pandemic has serious implications also for patients with other diseases. Here, we describe the effects of the pandemic on unrelated hematopoietic stem cell donation and transplantation from the perspective of DKMS, a large international donor registry. Especially, we cover the development of PBSC and bone...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01138-0

    authors： Mengling T,Rall G,Bernas SN,Astreou N,Bochert S,Boelk T,Buk D,Burkard K,Endert D,Gnant K,Hildebrand S,Köksaldi H,Petit I,Sauter J,Seitz S,Stolze J,Weber K,Weber M,Lange V,Pingel J,Platz A,Schäfer T,Schetelig J

    更新日期：2020-11-20 00:00:00

  • Hematopoietic stem cell transplantation activity in Europe 1999.

    abstract：:This survey on transplantation of hematopoietic stem cells from blood or bone marrow in Europe, the 10th in a series, reports the numbers of transplants performed in 1999 and concentrates on changes in indications and donor types. Members of the European Group for Blood and Marrow Transplantation and associated teams ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702995

    authors： Gratwohl A,Passweg J,Baldomero H,Urbano-Ispizua A,European Group for Blood and Marrow Transplantation (EBMT).

    更新日期：2001-05-01 00:00:00

  • The changing role of stem cell transplantation in childhood.

    abstract：:Over the past decade, relevant improvements and refinements have significantly changed the indications, technique and results obtained with allogeneic hematopoietic SCT (HSCT) in childhood. A fundamental turning point in the history of allogeneic HSCT is represented by the use of placental blood, which was first emplo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.45

    authors： Locatelli F,Giorgiani G,Di-Cesare-Merlone A,Merli P,Sparta V,Moretta F

    更新日期：2008-06-01 00:00:00

  • Are new conditioning regimens for transplants in acute myelogenous leukemia better?

    abstract：:Pretransplant conditioning regimens designed to decrease leukemia relapse and increase leukemia-free survival in allotransplants in acute myelogenous leukemia (AML) were developed recently. We review studies of new regimens containing drugs like busulfan, cytarabine, melphalan or etoposide as well as novel radiation s...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Aurer I,Gale RP

    更新日期：1991-04-01 00:00:00

  • Increased intensity of acute graft-versus-host disease after reduced-intensity bone marrow transplantation compared to conventional transplantation from an HLA-matched sibling in children.

    abstract：:Eight children underwent reduced-intensity stem cell transplantation (RIST) from an HLA-matched sibling. They received a fludarabine-melphalan based preparative regimen. Stem cell source was bone marrow, and GVHD prophylaxis consisted of cyclosporine A alone. Acute GVHD grade II-IV and grade III-IV were observed in fo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705285

    authors： Inoue M,Okamura T,Yasui M,Sawada A,Sakata N,Koyama M,Sakata A,Takeshita Y,Kouroki M,Yagi K,Kawa K

    更新日期：2006-03-01 00:00:00

  • Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.

    abstract：:The treatment of established veno-occlusive disease (VOD) of the liver with tissue plasminogen activator (tPA) has been disappointing. In attempts to improve upon these results we identified a subgroup of patients with consistently elevated bilirubin levels who did not meet conventional criteria for VOD (Susp VOD) but...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1702069

    authors： Schriber J,Milk B,Shaw D,Christiansen N,Baer M,Slack J,Tezcan H,Wetzler M,Herzig G

    更新日期：1999-12-01 00:00:00

  • Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.

    abstract：:We performed a retrospective analysis of the incidence, risk factors, and clinical outcome of hepatic veno-occlusive disease (VOD) in 50 children prepared for bone marrow transplantation with busulfan (16 mg/kg) and cyclophosphamide (200 mg/kg). The overall incidence of VOD was 28% (14/50). The incidence of VOD among ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Ozkaynak MF,Weinberg K,Kohn D,Sender L,Parkman R,Lenarsky C

    更新日期：1991-06-01 00:00:00

  • Allogeneic transplantation of purified CD34+ cells from peripheral blood: Spanish experience of 62 cases. Spanish Group of allo-PBT.

    abstract：:This report summarizes the Spanish experience of 62 cases of allogeneic transplantation of purified CD34+ cells from peripheral blood. HLA-identical sibling donors received G-CSF. After leukapheresis, peripheral blood progenitor cells were purified using one of two methods: Ceprate (n = 38), or Isolex 300 (n = 24). Si...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Urbano-Ispizua A,Solano C,Brunet S,de la Rubia J,Odriozola J,Zuazu J,Figuera A,Caballero D,Martínez C,García J,Sanz G,Torrabadella M,Alegre A,Pérez-Oteiza J,Jurado M,Oyonarte S,Sierra J,García-Conde J,Rozman C

    更新日期：1998-06-01 00:00:00

  • Combination antifungal therapy: what can and should we expect?

    abstract：:Invasive fungal infections are associated with significant morbidity and mortality among immunocompromised patients. Recent advances in antifungal development have afforded us more pharmacologic compounds to choose from when managing these fungal infections. The role of combination antifungal therapy has been well est...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1705687

    authors： Johnson MD,Perfect JR

    更新日期：2007-08-01 00:00:00

  • Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.

    abstract：:A second allograft was offered to 58 relapsed AML patients after conditioning with fludarabine 90-150 mg/m(2) and thiotepa 15 mg/kg, in most cases with active disease. Median age was 53 years (range 23-69), median time to relapse after the first allo-SCT was 326 (47-2189) days and median follow-up was 6.7 years. GVHD ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.267

    authors： Christopoulos P,Schmoor C,Waterhouse M,Marks R,Wäsch R,Bertz H,Finke J

    更新日期：2013-07-01 00:00:00

  • N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation.

    abstract：:Busulfan is currently used as a main component in the conditioning regimen prior to allogeneic stem cell transplantation (SCT). Several studies have shown a correlation between exposure to busulfan and transplantation-related liver toxicity, such as venoocclusive disease (VOD) in patients undergoing SCT. Busulfan is m...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704143

    authors： Sjöö F,Aschan J,Barkholt L,Hassan Z,Ringdén O,Hassan M

    更新日期：2003-08-01 00:00:00

  • Administration of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation in children with acute myelogenous leukemia: a note of caution.

    abstract：:A series of 22 consecutive pediatric patients undergoing ABMT for treatment of primary AML was reviewed in an efficacy analysis of recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF). Treatment with at least two cycles of chemotherapy and a standard conditioning regimen of busulfan and cycloph...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Calderwood S,Doyle JJ,Hitzler JK,Saunders EF,Freedman MH

    更新日期：1996-07-01 00:00:00

  • Increasing mixed chimerism and the risk of graft loss in children undergoing allogeneic hematopoietic stem cell transplantation for non-malignant disorders.

    abstract：:We performed quantitative PCR-based serial chimerism testing of whole blood (WB) and CD3+ cells and retrospectively correlated the results of chimerism tests and the risk of graft loss in children undergoing transplant for non-malignant disorders. Twenty-four children were included in this study. All patients initiall...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.89

    authors： Ozyurek E,Cowan MJ,Koerper MA,Baxter-Lowe LA,Dvorak CC,Horn BN

    更新日期：2008-07-01 00:00:00

  • HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation.

    abstract：:HLA-C matching is an important determinant of outcome after myeloablative unrelated donor (URD) hematopoietic stem cell transplantation. However, its importance in non-myeloablative stem cell transplantation (NST) is not known. We report a retrospective analysis of 111 patients who underwent URD NST, of whom 78 were 1...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1705315

    authors： Ho VT,Kim HT,Liney D,Milford E,Gribben J,Cutler C,Lee SJ,Antin JH,Soiffer RJ,Alyea EP

    更新日期：2006-05-01 00:00:00

  • Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.

    abstract：:Adoptive immunotherapy with allogeneic purified natural killer (NK) cell products might exert graft-versus-tumor alloreactivity with little risk of GVHD. In a prospective phase II study in two centers, we administered purified NK cell products to high-risk patients treated with haploidentical T-cell-depleted SCT. Sixt...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/bmt.2012.162

    authors： Stern M,Passweg JR,Meyer-Monard S,Esser R,Tonn T,Soerensen J,Paulussen M,Gratwohl A,Klingebiel T,Bader P,Tichelli A,Schwabe D,Koehl U

    更新日期：2013-03-01 00:00:00

  • Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.

    abstract：:Twenty-nine pediatric allogeneic bone marrow transplant (BMT) recipients, ages 2-17 years, were followed prospectively for cytomegalovirus (CMV) infection. Patients at risk received ganciclovir (GCV) prophylactically at a dose of 5 mg/kg/day i.v., 3 to 5 days per week, until day 100. Surveillance blood and urines were...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Canpolat C,Culbert S,Gardner M,Whimbey E,Tarrand J,Chan KW

    更新日期：1996-04-01 00:00:00

  • Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score.

    abstract：:Acute graft-versus-host disease (aGVHD) is a major cause of morbidity mortality in critically ill hematopoietic stem cell transplantation recipients. We assessed aGVHD trajectories in 191 allogeneic-HSCT recipients (age 42 (27-46)) admitted to our ICU between 2005 and 2015. aGVHD affected 130 (68%) patients (including...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-0857-x

    authors： Pichereau C,Lengliné E,Valade S,Michonneau D,Ghrenassia E,Lemiale V,Socié G,Azoulay E

    更新日期：2020-10-01 00:00:00

  • Engraftment-associated hypophosphatemia--the role of cytokine release and steep leukocyte rise post stem cell transplantation.

    abstract：:Hypophosphatemia associated with bone marrow transplantation has been infrequently reported. The suggested mechanism is phosphate uptake by the replicating cells. Various cytokines are associated with the development of hypophosphatemia. The present study evaluated the interrelationship between cytokine release, the r...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702761

    authors： Raanani P,Levi I,Holzman F,Grotto I,Brok-Simoni F,Avigdor A,Davidson J,Shpilberg O,Ben-Bassat I

    更新日期：2001-02-01 00:00:00

  • Autografting in Philadelphia (Ph)+ chronic myeloid leukaemia using cultured marrow: an update of a pilot study.

    abstract：:Incubation of CML marrow in long-term culture (LTC) conditions may result in selection of normal (Ph-) LTC-initiating cells (LTC-IC) as early as 10 days, and in production of Ph- clonogenic cells and mature end cells within 5 weeks. This was the rationale for using marrow cells from 10-day-old LTC to autograft nine ch...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700777

    authors： Coutinho LH,Chang J,Brereton ML,Morgenstern GR,Scarffe JH,Harrison CJ,Yin JA,Darbyshire PJ,Burdach S,Dexter TM,Testa NG

    更新日期：1997-05-01 00:00:00